Drier at 12 weeks
51% of subjects who took VESIcare once-daily 5 mg reported no incontinence episodes in their consecutive three-day diary prior to the end of the study, compared to 38% of subjects who were administered placebo.⁶

Drier at 1 year
60% of patients treated with VESIcare reported no incontinence episodes at the end of a 40-week, open-label extension safety study in a post hoc responder analysis.¹⁷

For first 4 weeks of extension, patients took 5 mg and for remaining 36 weeks were allowed flexible dosing of VESIcare 5 mg or 10 mg.
Primary objective was to assess safety and tolerability of long-term treatment.
Post hoc responder analysis in patients who reported incontinence at baseline and no incontinence episodes for 3 consecutive days prior to study visits.

Drier than tolterodine
59% of patients receiving VESIcare 5 mg or 10 mg reported no incontinence episodes at 12 weeks, versus 49% of receiving tolterodine 4 mg extended release in a head-to-head study (P=0.006).¹⁸ In terms of the study’s primary endpoint, mean change from baseline in micturitions per 24 hours, demonstrated VESIcare to be noninferior to tolterodine (P = 0.004).¹⁸

Results from a double-blind, double-dummy, 12-week study comparing efficacy and safety of VESIcare in a flexible-dosing regimen of 5 mg or 10 mg and tolterodine 4 mg extended release.
The primary endpoint, mean change from baseline in micturitions/24 h, demonstrated VESIcare to be noninferior to tolterodine (P=0.004).
The most common drug-related, treatment-emergent adverse events reported by patients were dry mouth (30.0%, 24.1%), constipation (6.4%, 2.5%), headache (2.7%, 3.6%), and dyspepsia (2.2%, 0.8%) with VESIcare (n=593) and tolterodine (n=607), respectively.

 Warning Time
 Warning Time is defined in one study as the duration from the first sensation of urgency to voiding.¹⁹ Because the difference between making it to the restroom and having an incontinence episode may be a matter of seconds, an increase in  Warning Time may help to improve some of your patients’ chances of staying drier.

VESIcare is the first once-daily OAB treatment that has demonstrated the ability to significantly increase Warning Time compared to placebo at the approved dose. The effects of VESIcare 5 and 10 mg on Warning Time were assessed in a 12-week, double-blind, placebo-controlled trial. The primary endpoint of the trial was mean change in urgency episodes per twenty-four hours. The median change in Warning Time from baseline for patients on VESIcare was 31.5 seconds, compared to 12 seconds for those on placebo.¹⁹

Results from a 12-week, placebo controlled study of the efficacy and safety of VESIcare 5 mg and 10 mg in a flexible-dosing regimen.
The primary endpoint, mean change in urgency episodes/24 h: VESIcare provided significantly greater reductions compared with placebo (P<0.0001).
Other secondary endpoints: VESIcare provided significantly greater reductions in micturitions/24 h and incontinence episodes/24 h compared to placebo (P<0.05); no difference was observed for nocturia-related endpoints compared to placebo.
The most common drug-related, treatment-emergent adverse events reported by patients were dry mouth (25.3%, 9.0%), constipation (14.8%, 9.3%), blurred vision (3.8%, 1.1%), dizziness (3.2%, 1.9%), and fatigue (2.7%, 1.1%) with VESIcare 5 mg or 10 mg and placebo, respectively.